{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:00Z","timestamp":1791945900270,"version":"4.3.4"},"reference-count":37,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aims to assess the risk of metabolic side effects among paediatric new users of antipsychotics in Sweden, focusing on differences between substances and sexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children aged 5\u201317\u2009years, who were new users of antipsychotics between 2014 and 2021, were identified using Swedish national health registers. Cox' models were fitted for children during first treatment with an antipsychotic, excluding those with eating disorders, yielding hazard ratios (HRs) for metabolic side effects with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5441 children were new users of antipsychotics. Of these, 399 (7.3%; 42% girls) received a new diagnosis or new treatment indicating a metabolic side effect, of which 139 cases during first\u2010line treatment and without an eating disorder diagnosis. Obesity was the most common metabolic side effect, accounting for 69% of the cases. In girls, significantly increased risks were observed for aripiprazole (HR 3.52, 95% CI 1.58\u20137.80), olanzapine (HR 6.99, 95% CI 2.34\u201320.93) and quetiapine (HR 4.87, 95% CI 1.97\u201312.04), compared with risperidone. Younger girls had higher risks. In boys, a significantly increased risk was found for aripiprazole (HR 2.21, 95% CI 1.37\u20133.56).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The overall risk of metabolic side effects is considerable, with higher relative risks in girls, especially younger girls. These findings highlight the need for carefully considered treatment and attentive monitoring when initiating antipsychotics in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70482","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:14:40Z","timestamp":1790075680000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden\u2014A Register\u2010Based Study"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-5895","authenticated-orcid":false,"given":"Elin Eyfells","family":"Kimland","sequence":"first","affiliation":[{"name":"Swedish Medical Products Agency  Uppsala Sweden"},{"name":"Department of Pharmacy, Faculty of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-3371","authenticated-orcid":false,"given":"Anders","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Swedish Medical Products Agency  Uppsala Sweden"},{"name":"Department of Pharmacy, Faculty of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-9951","authenticated-orcid":false,"given":"Sverre","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Region V\u00e4rmland  Karlstad Sweden"},{"name":"School of Medical Sciences \u00d6rebro University  \u00d6rebro Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-453X","authenticated-orcid":false,"given":"H\u00e5kan","family":"Jarbin","sequence":"additional","affiliation":[{"name":"Unit for Child and Adolescent Psychiatry, Department of Clinical Sciences Lund Lund University  Lund Sweden"},{"name":"Department of Child and Adolescent Psychiatry Region Halland  Halmstad Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-2405","authenticated-orcid":false,"given":"Elin","family":"Dahl\u00e9n","sequence":"additional","affiliation":[{"name":"Swedish Medical Products Agency  Uppsala Sweden"},{"name":"Department of Pharmacy, Faculty of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"\u201cRisperidone Summary of Product Characteristics (SmPC) \u201dEuropean Medicines Agency (EMA) accessed November 21 2025 https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"e_1_2_11_3_1","unstructured":"\u201cZiprasidone Summary of Product Characteristics (SmPC) \u201dEuropean Medicines Agency (EMA) accessed November 21 2025 https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"e_1_2_11_4_1","unstructured":"\u201cAripirazole Summary of Product Characteristics (SmPC) \u201dEuropean Medicines Agency (EMA) accessed November 21 2025 https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010021\u201005809\u20108"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010019\u201002711\u20103"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13945"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787\u2010026\u201002960\u20105"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00316"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787\u2010024\u201002545\u20100"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(22)00404\u20107"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.07.001"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787\u2010016\u20100905\u20107"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000523"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2020.0095.15"},{"key":"e_1_2_11_16_1","unstructured":"L\u00e4kemedelsverket \u201cNeuroleptika vid vissa barnpsykiatriska tillst\u00e5nd hos barn och ungdomar \u2013 behandlingsrekommendation \u201d2016 https:\/\/lakemedelsverket.se\/malgrupp\/Halso\u2010\u2010\u2010sjukvard\/Behandlings\u2010\u2010rekommendationer\/Behandlingsrekommendation\u2010\u2010\u2010listan\/Neuroleptika\u2010vid\u2010vissa\u2010barnpsykiatriska\u2010tillstand\u2010hos\u2010barn\u2010och\u2010ungdomar\/."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2014.04.023"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2015.0285"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2019.01.015"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20765"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2023.04.018"},{"key":"e_1_2_11_23_1","unstructured":"\u201cOlanzapine Summary of Product Characteristics (SmPC) \u201dEuropean Medicines Agency (EMA) accessed November 21 2025 https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"e_1_2_11_24_1","unstructured":"\u201cQuetiapine Summary of Product Characteristics (SmPC) \u201dEuropean Medicines Agency (EMA) accessed November 21 https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20104642(24)00098\u20101"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22r14490"},{"key":"e_1_2_11_27_1","first-page":"1","article-title":"Increased Use of Antipsychotics to Children and Adolescents \u2013 Monitoring of Effect and Safety Is Needed","volume":"122","author":"Dahlen E.","year":"2025","journal-title":"L\u00e4kartidningen"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.640377"},{"key":"e_1_2_11_29_1","unstructured":"\u201cData Open From the Statistiska Centralbyr\u00e5n (Statistics Sweden) \u201daccessed May 22 2025 http:\/\/www.scb.se\/."},{"key":"e_1_2_11_30_1","unstructured":"Ministry of Health and Social Affairs \u201cBenefits Act (2002:160 5\u00a7) \u201dThe Swedish Parliament accessed May 22 2025 https:\/\/www.riksdagen.se\/sv\/dokument\u2010och\u2010lagar\/dokument\/svensk\u2010forfattningssamling\/lag\u20102002160\u2010om\u2010lakemedelsformaner\u2010m\u2010m_sfs\u20102002\u2010160\/."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010018\u20100571\u2010z"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.2053"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21279"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.20900\/jpbs.20190013"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010024\u201001089\u2010w"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.650904"},{"key":"e_1_2_11_37_1","unstructured":"\u201cData Open From the National Patient Registry: Swedish National Board of Health and Welfare \u201daccessed May 22 2025 https:\/\/sdb.socialstyrelsen.se\/if_lak\/val.aspx."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2022.0230"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70482","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70482","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:58:09Z","timestamp":1791943089000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/pds.70482"],"URL":"https:\/\/doi.org\/10.1002\/pds.70482","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"2026-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70482"}}